Cargando…

The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

BACKGROUND: Several parameters of the tumor microenvironment, such as hypoxia, inflammation and angiogenesis, play a critical role in tumor aggressiveness and treatment response. A major question remains if these markers can be used to stratify patients to certain treatment protocols. The purpose of...

Descripción completa

Detalles Bibliográficos
Autores principales: De Schutter, Harlinde, Landuyt, Willy, Verbeken, Erik, Goethals, Laurence, Hermans, Robert, Nuyts, Sandra
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1097720/
https://www.ncbi.nlm.nih.gov/pubmed/15847702
http://dx.doi.org/10.1186/1471-2407-5-42
_version_ 1782123910275268608
author De Schutter, Harlinde
Landuyt, Willy
Verbeken, Erik
Goethals, Laurence
Hermans, Robert
Nuyts, Sandra
author_facet De Schutter, Harlinde
Landuyt, Willy
Verbeken, Erik
Goethals, Laurence
Hermans, Robert
Nuyts, Sandra
author_sort De Schutter, Harlinde
collection PubMed
description BACKGROUND: Several parameters of the tumor microenvironment, such as hypoxia, inflammation and angiogenesis, play a critical role in tumor aggressiveness and treatment response. A major question remains if these markers can be used to stratify patients to certain treatment protocols. The purpose of this study was to investigate the inter-relationship and the prognostic significance of several biological and clinicopathological parameters in patients with head and neck squamous cell carcinoma (HNSCC) treated by radiotherapy ± chemotherapy. METHODS: We used two subgroups of a retrospective series for which CT-determined tumoral perfusion correlated with local control. In the first subgroup (n = 67), immunohistochemistry for carbonic anhydrase IX (CA IX) and glucose transporter-1 (GLUT-1) was performed on the pretreatment tumor biopsy. In the second subgroup (n = 34), enzyme linked immunosorbent assay (ELISA) was used to determine pretreatment levels of the cytokines vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) in serum. Correlation was investigated between tumoral perfusion and each of these biological markers, as well as between the markers mutually. The prognostic value of these microenvironmental parameters was also evaluated. RESULTS: For CA IX and GLUT-1, the combined assessment of patients with both markers expressed above the median showed an independent correlation with local control (p = 0.02) and disease-free survival (p = 0.04) with a trend for regional control (p = 0.06). In the second subgroup, IL-6 pretreatment serum level above the median was the only independent predictor of local control (p = 0.009), disease-free survival (p = 0.02) and overall survival (p = 0.005). CONCLUSION: To our knowledge, we are the first to report a link in HNSCC between IL-6 pretreatment serum levels and radioresistance in vivo. This link is supported by the strong prognostic association of pretreatment IL-6 with local control, known to be the most important parameter to judge radiotherapy responses. Furthermore, the combined assessment of CA IX and GLUT-1 correlated independently with prognosis. This is a valuable indication that a combined approach is important in the investigation of prognostic markers.
format Text
id pubmed-1097720
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10977202005-05-12 The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy De Schutter, Harlinde Landuyt, Willy Verbeken, Erik Goethals, Laurence Hermans, Robert Nuyts, Sandra BMC Cancer Research Article BACKGROUND: Several parameters of the tumor microenvironment, such as hypoxia, inflammation and angiogenesis, play a critical role in tumor aggressiveness and treatment response. A major question remains if these markers can be used to stratify patients to certain treatment protocols. The purpose of this study was to investigate the inter-relationship and the prognostic significance of several biological and clinicopathological parameters in patients with head and neck squamous cell carcinoma (HNSCC) treated by radiotherapy ± chemotherapy. METHODS: We used two subgroups of a retrospective series for which CT-determined tumoral perfusion correlated with local control. In the first subgroup (n = 67), immunohistochemistry for carbonic anhydrase IX (CA IX) and glucose transporter-1 (GLUT-1) was performed on the pretreatment tumor biopsy. In the second subgroup (n = 34), enzyme linked immunosorbent assay (ELISA) was used to determine pretreatment levels of the cytokines vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) in serum. Correlation was investigated between tumoral perfusion and each of these biological markers, as well as between the markers mutually. The prognostic value of these microenvironmental parameters was also evaluated. RESULTS: For CA IX and GLUT-1, the combined assessment of patients with both markers expressed above the median showed an independent correlation with local control (p = 0.02) and disease-free survival (p = 0.04) with a trend for regional control (p = 0.06). In the second subgroup, IL-6 pretreatment serum level above the median was the only independent predictor of local control (p = 0.009), disease-free survival (p = 0.02) and overall survival (p = 0.005). CONCLUSION: To our knowledge, we are the first to report a link in HNSCC between IL-6 pretreatment serum levels and radioresistance in vivo. This link is supported by the strong prognostic association of pretreatment IL-6 with local control, known to be the most important parameter to judge radiotherapy responses. Furthermore, the combined assessment of CA IX and GLUT-1 correlated independently with prognosis. This is a valuable indication that a combined approach is important in the investigation of prognostic markers. BioMed Central 2005-04-25 /pmc/articles/PMC1097720/ /pubmed/15847702 http://dx.doi.org/10.1186/1471-2407-5-42 Text en Copyright © 2005 De Schutter et al; licensee BioMed Central Ltd.
spellingShingle Research Article
De Schutter, Harlinde
Landuyt, Willy
Verbeken, Erik
Goethals, Laurence
Hermans, Robert
Nuyts, Sandra
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
title The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
title_full The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
title_fullStr The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
title_full_unstemmed The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
title_short The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
title_sort prognostic value of the hypoxia markers ca ix and glut 1 and the cytokines vegf and il 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1097720/
https://www.ncbi.nlm.nih.gov/pubmed/15847702
http://dx.doi.org/10.1186/1471-2407-5-42
work_keys_str_mv AT deschutterharlinde theprognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT landuytwilly theprognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT verbekenerik theprognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT goethalslaurence theprognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT hermansrobert theprognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT nuytssandra theprognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT deschutterharlinde prognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT landuytwilly prognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT verbekenerik prognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT goethalslaurence prognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT hermansrobert prognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy
AT nuytssandra prognosticvalueofthehypoxiamarkerscaixandglut1andthecytokinesvegfandil6inheadandnecksquamouscellcarcinomatreatedbyradiotherapychemotherapy